Registry of Lobbyists
| Subject matters | Details | Categories |
|---|---|---|
|
Consumer Issues, Health, Industry
|
Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework.
|
Policies or Program
|
|
Health, Industry, Research and Development
|
Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda.
|
Policies or Program
|
|
Consumer Issues, Health, Industry
|
Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries
|
Policies or Program
|
|
Health, Industry, Intellectual Property
|
Patented Medicine Prices Review Board (PMPRB) Regulations as related to reporting requirements and pricing guidelines.
|
Regulation
|
|
Health, Industry, Intellectual Property
|
Patented Medicines (Notice of Compliance) Regulations as it relates to regulation of intellectual property for therapeutic products. Novartis is working with our industry associations (Innovative Medicines Canada and BIOTECanada) to provide a written response to Guideline consultation process and will provide our own corporate submission.
|
Regulation
|
|
Health, Industry
|
Patent Medicines Pricing Review Board reforms, regarding both the revised regulations and draft guidelines
|
Regulation
|
|
Health, Industry, Research and Development
|
R&D requirements set forth through the Patent Medicines Pricing Review Board (PMPRB)
|
Regulation, Policies or Program
|
|
Health, Industry, Research and Development
|
Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
|
Policies or Program
|
|
Health, Industry, Intellectual Property, Research and Development
|
Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, National Pharmacare, Intellectual property as well as pricing reforms (PMPRB)
|
Policies or Program
|
Address:
700 St-Hubert St., Suite 100
Montreal, QC H2Y 0C1
Canada
Telephone number:
514-631-6775
Shona Kinley, Director, Public Affairs and Government Relations
Novartis Pharmaceuticals Canada Inc. / Novartis Pharmaceuticals Canada Inc. is not a coalition.
The activities of Novartis Pharmaceuticals Canada Inc. / Novartis Pharmaceuticals Canada Inc. are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Novartis Pharmaceuticals Canada Inc. / Novartis Pharmaceuticals Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Jonathan Ingraham | Public offices held
Firm: Gowling WLG / Gowling WLG